SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses

By M. Mandolesi, D. Sheward, L. Hanke, Junjie Ma, P. Pushparaj, L. P. Vidakovics, Changil Kim, K. Loré, X. C. Dopico, J. Coquet and 3 more. 2020

20 citations recorded by the source corpus.

The outbreak and spread of SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), the cause of coronavirus disease 2019 (COVID-19), is a current global health emergency and a prophylactic vaccine is needed urgently. The spike glycoprotein of SARS-CoV-2 mediates entry into host cells, and thus is a target for neutralizing antibodies and vaccine design. Here we show that adjuvanted protein immunization with SARS-CoV-2 spike trimers, stabilized in prefusion conformation 1, results in potent antibody responses in mice and rhesus macaques with neutralizing antibody titers orders of magnitude greater than those typically measured in serum from SARS-CoV-2 seropositive humans. Neutralizing antibody responses were observed after a single dose, with exceptionally high titers achieved after boosting. Furthermore, neutralizing antibody titers elicited by a dose-sparing regimen in mice were similar to those obtained from a high dose regimen. Taken together, these data strongly support the development of adjuvanted SARS-CoV-2 prefusion-stabilized spike protein subunit vaccines.

Subfields: Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Frieman
2. Haixia Zhou
3. P. Reed

Citations in the corpus

• First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine (2020, methodology): “provided protection against SARS-CoV-2 challenge.(8,9) In addition, CD4 and CD8 T-cell responses were induced with a T helper 1 (Th1) dominant phenotype.”